Imagine managing a condition like chronic kidney disease (CKD) alongside high blood pressure—it's like walking a tightrope where one wrong step could lead to serious health complications. Recent groundbreaking research is turning heads by suggesting that nearly every adult in this situation might gain from aiming for an even stricter blood pressure goal. But here's where it gets controversial: could this mean rethinking long-held medical guidelines, and what if it challenges how we approach treatment for those without certain risk markers? Let's dive into the details and explore why this could be a game-changer.
A fresh analysis from the Systolic Blood Pressure Intervention Trial (SPRINT) reveals that almost all participants with hypertension and nondiabetic CKD in stages 3–4 experienced advantages from targeting a systolic blood pressure (the top number in your BP reading) below 120 mm Hg, rather than the more lenient goal of under 140 mm Hg. This study, unveiled at the American Society of Nephrology (ASN) Kidney Week 2025 (held November 5-9, 2025, in Houston, Texas), was presented by Alan Vera, a medical student at the University of California Davis. For those new to these terms, CKD affects the kidneys' ability to filter waste, often progressing to stages where function is moderately to severely impaired, and hypertension adds the burden of persistently high blood pressure, which can accelerate kidney damage.
Vera and his team tackled the ongoing debate over ideal blood pressure targets for people with hypertension and CKD. They employed a clever approach: using predicted risks and simulated preferences to calculate the personalized net benefits of aggressive blood pressure reduction. In simpler terms, they ran a benefit-harm trade-off analysis on 2,012 CKD participants from SPRINT. This involved statistical models (like Cox models) to estimate the absolute risk differences for major outcomes, including overall death, heart-related events, cognitive issues (such as memory problems), and downsides like kidney injuries or fainting from intense treatment.
The study group was diverse, with an average age of 73 years (give or take 9 years), about 43% women, 31% Black participants, and baseline kidney function measured by eGFR (estimated glomerular filtration rate, which gauges how well kidneys clean blood) at around 46 ml/min/1.73m², plus moderate albuminuria (protein leaking into urine) levels averaging 16 mg/g (with a range from 7 to 56). When they modeled scenarios where participants highly valued the upsides of lower BP—like fewer deaths, heart risks, and cognitive declines—over the risks such as kidney flare-ups or dizziness, a stunning 100% showed a positive net benefit from the stricter target, with a middle-ground benefit of 6.4%.
And this is the part most people miss: even in a balanced simulation where benefits and harms were weighed equally, 90% still came out ahead, with an average net gain of 2.2%. Intriguingly, those with more severe CKD (eGFR between 20–44 ml/min/1.73m²) reaped even bigger rewards from lower targets compared to those in earlier stages (eGFR 45–59 ml/min/1.73m²), outweighing the extra treatment risks. As Vera explained in a statement, this personalization could empower doctors and patients in shared decision-making, tailoring advice based on individual risks and priorities.
These results align perfectly with KDIGO (Kidney Disease: Improving Global Outcomes) Guidelines, which advocate for that <120 mm Hg systolic target in hypertensive CKD cases. ASN highlighted how this data might help overcome the 'therapeutic inertia'—that hesitation to ramp up treatments—often seen when intensifying BP control for CKD patients.
But wait, the Kidney Week buzz didn't stop there. Shifting gears, another presentation threw a wrench into guidelines about SGLT2 inhibitors (a class of drugs originally for diabetes that also protect kidneys). Natalie Staplin, PhD, an Associate Professor of Medical Statistics at the University of Oxford, shared a massive meta-analysis of 58,816 people from eight trials, including 48,946 with diabetes and 9,870 without. Shockingly, SGLT2 inhibitors slowed the worsening of CKD (measured by eGFR decline) by 57% in diabetics and 41% in non-diabetics, regardless of diabetes status. They also cut kidney progression risks by 32%, acute kidney injury by 21%, overall deaths by 13%, and hospital stays by 11%, with effects holding strong across all groups—even those with low albuminuria levels.
In a candid chat with HCPLive, Staplin urged reconsidering the need for high albuminuria thresholds in guidelines, suggesting SGLT2 inhibitors could benefit everyone with CKD, not just those with elevated urine protein. This challenges the status quo, potentially broadening access but sparking debates on cost, side effects, and whether we're over-medicating without clear cutoffs. Could guidelines be too restrictive, or is there a risk of unnecessary treatments?
What do you think? Does this push for stricter BP targets feel empowering or overwhelming? And should we ditch albuminuria limits for SGLT2 inhibitors across the board—share your views in the comments! Your thoughts could fuel important discussions on personalized medicine for CKD.
References
Vera AR, Scherzer R, Kravitz RL, et al. Individualized Net Benefit of Intensive Blood Pressure Lowering Among Persons with CKD in SPRINT. Presented at: ASN Kidney Week. Houston, Texas. November 05-09, 2025. # FR-OR040
Trial Analysis Reveals Almost All Adults with Hypertensive Chronic Kidney Disease Would Benefit from Intensive Blood Pressure Lowering. News release. ASN. November 7, 2025. https://www.newswise.com/articles/trial-analysis-reveals-almost-all-adults-with-hypertensive-chronic-kidney-disease-would-benefit-from-intensive-blood-pressure-lowering
Staplin N, Roddick AJ, Haynes R, Herrington WG. Net Effects of SGLT2 Inhibitors by Diabetes Status and Albuminuria. Presented at: ASN Kidney Week. Houston, Texas. November 05-09, 2025. #FR-OR086
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
